



**LIVER
UPDATE**

26th June 2016, Hyderabad

“Liver Update”:

"The Liver Update CME was held at Hyderabad under the banner of Asian Society of Continuing Medical Education.

The CME was designed to get all the Hepatologist, Gastroenterologist and General Physician on one platform for exchanging their views and sharing their clinical experiences with others about the challenges in the management of Liver diseases. Well known Hepatologist, Gastroenterologist and General Physician were invited to share their knowledge and Experience.

The Introductory speech was given by Asian Society. He emphasized the main role played by Asian Society of Continuing Medical Education and how important it is to spread the knowledge known to select few to the practicing Doctors at large.

The CME was attended by 58 Doctors all round India.

Date:

- 26th June 2016

Places and Venues:

- Hotel Mercure, Somajiguda, Hyderabad

Total Participants: 58





Faculty:

Course Director:

- **Dr. P. N Rao**

Chairpersons:

- **Dr. D. Chandra Sekhar Reddy**
- **Dr. P. Shravan Kumar**
- **Dr. G. Mohan Reddy**
- **Dr. Santosh Enaganti**
- **Dr. E Ramanjaneyulu**
- **Dr. PBSS Raju**
- **Dr. B. Surender Reddy**
- **Dr. B. Ravi Shankar**
- **Dr. Parimal Lavate**
- **Dr. Kiran Peddi**

Speaker Topic wise:

- **Dr. Pandurang Rao**
- **Dr. Ajit Kumar (NIMS)**
- **Dr. Sethu Babu**
- **Dr. Mithun Sharma**
- **Dr. Uma Devi (Gandhi)**
- **Dr. Sharat Putta**
- **Dr. Parimal Lavate**
- **Dr. P. N. Rao (AIG)**
- **Dr. Naveen Polavarpu**





drugs is urgently needed. Progress has been made in the development and testing of new therapeutics against chronic HBV infection

- **Dr. Mithun Sharma** talked on HCV Treatment experienced (PR and SOFO).

The summary of topic is –

- a) Combination Sofosbuvir and Simeprevir Is Very Effective and Well Tolerated for the Treatment of Recurrent Hepatitis C After Liver Transplant.
 - b) Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience.
 - c) Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin.
 - d) Renal Function in Patients Treated for Recurrent Hepatitis C With Sofosbuvir and Simeprevir.
 - e) Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Decompensated Cirrhosis
- **Dr. Uma Devi (Gandhi)** talked on HCV: HCC and New Anti Viral DAAs : -

Direct-acting antiviral agents (DAAs)—the protease inhibitors boceprevir and telaprevir to pegylated interferon α -2a/b and ribavirin revolutionized the treatment of HCV infection by increasing cure rates across all fibrosis scores in patients with genotype 1 HCV infection. Patients with advanced fibrosis or cirrhosis are the most difficult to treat, and the addition of DAAs increases treatment side effects as well as potency.





SNAPSHOTS



